2 11, 2022 Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine but strong initial responses to a third dose Neal Evan Caminsky2022-11-15T09:12:42-05:00November 2, 2022|Funded Research Results, Pillar 1|
2 11, 2022 Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccine Neal Evan Caminsky2022-11-15T09:12:39-05:00November 2, 2022|Funded Research Results, Pillar 1|
2 11, 2022 Identifying markers of emerging SARS-CoV-2 variants in patients with secondary immunodeficiency Neal Evan Caminsky2022-11-15T09:12:37-05:00November 2, 2022|Funded Research Results, Pillar 3|
25 10, 2022 Floors are a new tool for tracking SARS-CoV-2 and other viruses Neal Evan Caminsky2022-11-28T12:35:02-05:00October 25, 2022|Hot Topic|
17 10, 2022 CoVaRR-Net Recommendations on Vaccine Hesitancy in Children Neal Evan Caminsky2022-10-17T17:03:55-04:00October 17, 2022|Recommendations|
4 10, 2022 Cytokines and lipid mediators of inflammation in lungs of SARS-CoV-2 infected mice Neal Evan Caminsky2022-11-15T09:14:07-05:00October 4, 2022|Funded Research Results, Pillar 3|
30 09, 2022 A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS -CoV-2 infection Neal Evan Caminsky2022-11-15T09:14:05-05:00September 30, 2022|Funded Research Results, Pillar 3|
27 09, 2022 Human coronaviruses disassemble processing bodies Neal Evan Caminsky2022-11-15T09:14:02-05:00September 27, 2022|Funded Research Results, Pillar 3|
26 09, 2022 Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants Neal Evan Caminsky2022-11-15T09:14:00-05:00September 26, 2022|Funded Research Results, Pillar 3|
6 09, 2022 A bivalent COVID-19 vaccine tailored to Omicron BA.1 is approved in Canada, however the need remains for a pan-coronavirus vaccine Neal Evan Caminsky2022-09-07T10:41:25-04:00September 6, 2022|Hot Topic|
